Twist Bioscience reported third-quarter fiscal 2026 results with record revenue of $118.4 million, up more than 23% year-over-year, and a gross margin of 52.8%. The company posted a net loss of $35.1 million for the quarter and adjusted EBITDA of $(11.3) million. Twist raised its full-year 2026 revenue guidance to $456–$457 million and reiterated guidance for adjusted EBITDA breakeven in Q4 FY2026.

Financial Highlights

  • Total revenue: $118.4 million for the three months ended June 30, 2026, versus $96.1 million in Q3 FY2025.
  • Gross margin: 52.8% for Q3 FY2026 (sequential increase from 51.6% in Q2 FY2026).
  • Cost of revenues: $55.9 million for Q3 FY2026 (compared with $44.8 million in Q3 FY2025).
  • Net (loss) income: $(35.1) million, or $(0.56) per diluted share, for Q3 FY2026 (compared with net income $20.4 million, or $0.33 per diluted share, in Q3 FY2025).
  • Adjusted EBITDA: $(11.3) million for Q3 FY2026 (compared with $(8.0) million in Q3 FY2025).

Business Highlights

  • Segment performance: DNA Synthesis and Protein Solutions revenue grew 39% year-over-year to $56.6 million and increased 6% sequentially; NGS Applications revenue grew 12% year-over-year to $61.8 million and increased 8% sequentially.
  • Customer and volume trends: Shipped products to ~2,650 customers in Q3 FY2026 (up from ~2,480 a year earlier) and physically shipped ~369,000 genes in the quarter versus ~237,000 in Q3 FY2025.
  • Product and commercial activity: Commercial launch of Twist Complex Genes following an early access period; inaugural Investor Day hosted at the Wilsonville, OR site.
  • Scientific impact: Twist Comprehensive Viral Research Panel supported identification of a rare Ebola strain in the Democratic Republic of the Congo that PCR tests missed.
  • Balance sheet and liquidity: Cash, cash equivalents and short-term investments of approximately $167 million as of June 30, 2026.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.